Forgot your password?

Forgot your username?

database > company
POZEN
Biotech Specialty Pharma
1414 Raleigh Road, Suite 400
Chapel Hill, NC 27517 USA
phone:(919) 913-1030
fax:919-913-1039
Symbol POZN
Exchange Nasdaq
Founded 1996
Employees
www.pozen.com
Research Sector Biotech Specialty Pharma
Summary Description
Drug therapies for a varity of illness with a focus on migraines.
Management
John R. Plachetka, Pharm.D., Chairman, President and Chief Executive Officer; Elizabeth A. Cermak, Executive Vice President, Chief Commercial Officer; John G. Fort, M.D., Chief Medical Officer; William L. Hodges, Senior Vice President Finance & Administration and Chief Financial Officer; Everadus Orlemans, Ph.D., Senior Vice President, Product Development
Ownership
Financials Mkt Cap :295


* numbers in thousands
 

Keywords
sumatriptan, naproxen sodium, non-steroidal, naproxen, osteoarthritis

Comment | Printable Version | Modify profile |
Updated: Jan. 29, 2012

Description
POZEN is pharmaceutical company developing therapeutic advancements in a cost effective manner. POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company's drug candidates.
Products / Services
POZEN has developed a large product pipeline geared towards migraines.
Market / Customers
POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed.
Strategy
Unlike a traditional pharmaceutical company that operates and funds major functions in-house, POZEN works with strategic partners to execute pre-clinical and clinical studies, develop novel formulations and manufacture the product. Experienced senior staff maintains control over these key functions through effective program management, which includes managing and coordinating these activities, analyzing and interpreting all data and handling FDA interactions. POZEN's business model enables the company to develop its products quickly and efficiently, while minimizing costs.


2012-02-09-670